ASPIRING TO IMPACT PATIENT CARE

We discover and develop new drugs in several therapeutic areas where we believe we can make a significant impact on the disease and its management.

2.1_A_mansmiling

Proven Expertise

Our discovery and development efforts are focused on a core set of therapeutic areas where we have proven expertise and where we believe we can have an even greater impact on the disease and how it is managed. These core areas of focus include immunology, kidney disease, liver disease, neuroscience, oncology and women’s health. We are investigating both small and large molecule approaches, and our internal research efforts are balanced with external collaborations across industry, academia and healthcare authorities.

See the medicines we're developing in these areas in Pipeline.


Addressing Serious Health Issues

IMMUNOLOGY

As leading experts in autoimmune diseases and therapies, AbbVie is focused on developing new medicines to address chronic progressive diseases in the field of immunology, including rheumatology and dermatology. AbbVie is investigating several diseases which have few or no treatments, including uveitis, hidradenitis suppurativa, pediatric Crohn’s disease, osteoarthritis and lupus. In addition, we are progressing next-generation therapies in rheumatoid arthritis with the objective to improve the current standard of care.


KIDNEY DISEASE

Kidney Disease affects 50 million people in the U.S. and Europe alone. We are researching potential therapies for CKD resulting from diabetes and for acute kidney injury in association with major surgeries.


LIVER DISEASE

Our antiviral program focuses on the development of treatments for chronic hepatitis C virus (HCV), a liver disease that affects more than 160 million people worldwide, with approximately three to four million new cases of infection every year. HCV infections potentially lead to long-term complications and chronic liver disease. AbbVie scientists are investigating a new all oral combination treatment regimen that is interferon-free for patients with genotype 1 HCV. Genotype 1 HCV represents the most prevalent patient type in the U.S. and Western Europe. We are committed to advancing science while finding the best treatment options for patients.


NEUROSCIENCE

Our current innovative research focuses on compounds that have the potential to treat a variety of chronic disabling neurological conditions. We have several compounds in the early and advanced investigational phases for diseases such as cognitive impairment associated with schizophrenia, Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS) — all of which affect millions of people worldwide.


ONCOLOGY

Our research is committed to discovering and developing targeted therapies that work against the processes cancer cells need to survive. AbbVie’s oncology pipeline includes multiple new molecules in clinical trials being studied in more than 15 cancers and tumor types, including some of the most widespread and difficult-to-treat, such as multiple myeloma and chronic lymphocytic leukemia.


WOMEN'S HEALTH

AbbVie is currently investigating a treatment for symptoms related to endometriosis and uterine fibroids. Each affects more than 16 million women throughout the world. Both conditions are highly prevalent and are associated with a number of symptoms including pain, bleeding and infertility.

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?

EXIT ABBVIE.COM

The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site.

As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to continue to this product-specific site?

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?